Fresenius Medical Care AG & Co. (FMS) Downgraded by ValuEngine

Share on StockTwits

ValuEngine lowered shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a hold rating to a sell rating in a research report released on Wednesday.

A number of other research analysts have also commented on FMS. Zacks Investment Research raised shares of Fresenius Medical Care AG & Co. from a strong sell rating to a hold rating in a research report on Tuesday, July 3rd. Credit Suisse Group lowered shares of Fresenius Medical Care AG & Co. from an outperform rating to a neutral rating in a research report on Thursday, July 5th. Bank of America started coverage on shares of Fresenius Medical Care AG & Co. in a research report on Monday, July 9th. They set a buy rating for the company. Royal Bank of Canada reaffirmed a neutral rating on shares of Fresenius Medical Care AG & Co. in a research report on Tuesday, July 31st. Finally, DZ Bank reissued a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, August 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $60.00.

Shares of FMS opened at $40.44 on Wednesday. The stock has a market cap of $24.46 billion, a PE ratio of 18.30, a P/E/G ratio of 1.89 and a beta of 0.80. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.37 and a quick ratio of 1.11. Fresenius Medical Care AG & Co. has a 52 week low of $39.74 and a 52 week high of $57.94.

Fresenius Medical Care AG & Co. (NYSE:FMS) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.54 EPS for the quarter, missing the Zacks’ consensus estimate of $0.60 by ($0.06). The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.28 billion. Fresenius Medical Care AG & Co. had a net margin of 11.65% and a return on equity of 10.78%. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.89 EPS. Equities analysts predict that Fresenius Medical Care AG & Co. will post 2.46 EPS for the current year.

Large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC acquired a new position in Fresenius Medical Care AG & Co. in the second quarter worth about $106,000. Destination Wealth Management acquired a new position in Fresenius Medical Care AG & Co. in the second quarter worth about $158,000. Mount Yale Investment Advisors LLC acquired a new position in Fresenius Medical Care AG & Co. in the second quarter worth about $192,000. Intercontinental Wealth Advisors LLC acquired a new position in Fresenius Medical Care AG & Co. in the second quarter worth about $203,000. Finally, Cibc Bank USA acquired a new position in Fresenius Medical Care AG & Co. in the third quarter worth about $215,000. 2.46% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA provides products and services for patients with chronic kidney failure. The company’s products include dialysis machines, dialyzers and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis.

Read More: Return on Investment (ROI)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Loom Network  Reaches Market Capitalization of $29.30 Million
Loom Network Reaches Market Capitalization of $29.30 Million
DeltaCredits Hits 24 Hour Volume of $0.00
DeltaCredits Hits 24 Hour Volume of $0.00
Zacks: Brokerages Expect Eventbrite Inc  Will Announce Quarterly Sales of $72.90 Million
Zacks: Brokerages Expect Eventbrite Inc Will Announce Quarterly Sales of $72.90 Million
Zacks: Analysts Expect Aramark  Will Announce Earnings of $0.64 Per Share
Zacks: Analysts Expect Aramark Will Announce Earnings of $0.64 Per Share
Zacks: Brokerages Anticipate QuinStreet Inc  Will Post Earnings of $0.12 Per Share
Zacks: Brokerages Anticipate QuinStreet Inc Will Post Earnings of $0.12 Per Share
Mixin  Price Tops $66.82
Mixin Price Tops $66.82


© 2006-2018 Ticker Report